However, in our recently performed extensive MS-based analysis of the primary CML immunopeptidome, we could not identify any naturally HLA-presented peptides encompassing BCR-ABL- or ABL-BCR-derived neoepitopes (68), keeping in mind that especially for MS-based immunopeptidomics, absence of evidence does not equal evidence of absence. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.